Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
3B Pharmaceuticals GmbH
Amgen Inc
Antag Therapeutics ApS
Bain Biotech ApS
Carmot Therapeutics Inc
D&D Pharmatech Co Ltd
Eli Lilly and Co
Gmax Biopharm LLC
Great Bay Bio Holdings Ltd
Hanmi Pharmaceuticals Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Kariya Pharmaceuticals IVS
Longevity Biotech Inc
Novo Nordisk AS
Onegene Biotechnology Inc
Sciwind Biosciences Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Viking Therapeutics Inc
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
(semaglutide + GIP alogue) - Drug Profile
Product Description
Mechanism Of Action
History of Events
3B-401 - Drug Profile
Product Description
Mechanism Of Action
AMG-133 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CT-868 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DAJC-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DD-03 - Drug Profile
Product Description
Mechanism Of Action
DR-10624 - Drug Profile
Product Description
Mechanism Of Action
DR-10625 - Drug Profile
Product Description
Mechanism Of Action
DR-10627 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DR-10628 - Drug Profile
Product Description
Mechanism Of Action
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
GIPR AGONIST LA II - Drug Profile
Product Description
Mechanism Of Action
GMA-106 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HS-20094 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KP-405 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LBT-6030 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3437943 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3493269 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-3537021 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OGB-21501 - Drug Profile
Product Description
Mechanism Of Action
Peptides to Antagonize GIPR for Obesity - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombint Peptide to Activate GIPR for Type I Diabetes - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide 1 to Agonize GIPR for Alzheimer’s Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestil and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
THDBH-120 - Drug Profile
Product Description
Mechanism Of Action
THDBH-121 - Drug Profile
Product Description
Mechanism Of Action
tirzepatide - Drug Profile
Product Description
Mechanism Of Action
History of Events
VK-2735 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XW-003 + XW-017 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZP-6590 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
Featured News & Press Releases
Jul 07, 2022: Eli Lilly Japan and Mitsubishi Tabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist “Tirzepatide”
Jun 10, 2022: Lilly eyes weight loss are for diabetes drug tirzepatide after positive data
Jun 08, 2022: Sciwind Biosciences to present data from its GLP-1 Program at The Intertiol Liver Congress EASL 2022
Jun 06, 2022: New alyses of Mounjaro (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association’s 82nd Scientific Sessions
Jun 04, 2022: SURMOUNT-1 Study Finds Individuals with Obesity Lost up to 22.5% of their Body Weight when Taking Tirzepatide
Jun 04, 2022: Lilly’s SURMOUNT-1 results published in The New England Jourl of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
Jun 03, 2022: Tirzepatide slowed progression of chronic kidney disease in patients with type 2 diabetes with increased cardiovascular risk
May 16, 2022: Lilly’s Mounjaro receives FDA approval for type 2 diabetes treatment
Apr 28, 2022: Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
Apr 26, 2022: AMRA Medical’s MRI-based body composition measurements used in Lilly’s SURPASS-3 tirzepatide sub-study
Apr 08, 2022: Announcement of Huadong Medicine on obtaining the approval notice of drug clinical trial for its holding subsidiary
Jan 10, 2022: Viking Therapeutics announces initiation of phase 1 clinical trial of VK2735, company’s lead dual GLP-1/GIP receptor agonist
Nov 11, 2021: Gmax’s GMA106, second generation obesity/T2DM/SH mAb gives first in human dose
Nov 01, 2021: Viking Therapeutics presents preclinical data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Oct 20, 2021: Lilly’s tirzepatide reduces body weight in Phase III type 2 diabetes trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Discontinued Products, 2022